ISSN: 1471-2598

Journal Home

Journal Guideline

Expert Opinion on Biological Therapy Q1 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Expert Opinion on Biological Therapy is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 102. It has a price of 4000 €. It has an SJR impact factor of 1,104 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,104.

Expert Opinion on Biological Therapy focuses its scope in these topics and keywords: therapy, treatment, vaccine, multiple, conjugate, cancer, cell, enterocolitisadvances, endometrial, diseasefrom, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Clinical Biochemistry (Q1) Drug Discovery (Q1) Pharmacology (Q1)

Price

4000 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,104

SJR Impact factor

102

H Index

129

Total Docs (Last Year)

440

Total Docs (3 years)

8646

Total Refs

1740

Total Cites (3 years)

395

Citable Docs (3 years)

3.72

Cites/Doc (2 years)

67.02

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Protein & Cell Q1
Molecular Therapy Q1
Nature Reviews Drug Discovery Q1
Medicinal Research Reviews Q1
Cell Chemical Biology Q1

Compare this journals

Aims and Scope

Best articles by citations

Angiogenesis, views and news. The 93rd Annual Meeting of the American Association for Cancer Research

Fighting infection using immunomodulatory agents

Recent advances in vaccines for leishmaniasis

Gene transfer to induce angiogenesis in myocardial and limb ischaemia

VEGF antagonists

Inhibition of hepatitis viral replication by siRNA

Use of bacteria as anticancer agents

Defensive applications of gene transfer technology in the face of bioterrorism: DNA-based vaccines and immune targeting

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

Chemical and biological properties of polymer-modified proteins

Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7') in patients with metastatic melanoma

Current status of adoptive immunotherapy of malignancies

SHOW MORE ARTICLES

Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours

Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy

Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9

Development of immunotherapeutic strategies for HIV-1

Platelet-derived growth factor applications in periodontal and peri-implant bone regeneration

Head and neck cancer: Gene therapy approaches. Part 1: Adenoviral vectors

Development of 2A peptide-based strategies in the design of multicistronic vectors

Interleukin-5: a novel target for asthma therapy

Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?

Prospects and challenges for use of CAR T cell therapies in solid tumors

The choroid plexus: function, pathology and therapeutic potential of its transplantation

Small molecules for small minds? The case for biologic pharmaceuticals